Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring ovarian cancer, platinum/taxane-refractory chemotherapy, Persistent, Recurrent
Eligibility Criteria
Inclusion criteria: Must have a screening CA-125 of greater than or equal to 40 U/ml. Must have received only one prior platinum/taxane-based chemotherapy regimen. Blood tests will be done to check if blood counts are adequate for taking part in the study. Exclusion criteria: Received more than 1 chemotherapy regimen in the past or have less than adequate liver and kidney function. Females who are pregnant or nursing. Any unstable, pre-existing major medical condition or history of other cancers. Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site